Biography

Mr. Pucci is the retired CEO and a former member of the Board of Directors of ArQule, Inc., a biopharmaceutical company engaged in the research and development of targeted therapeutics that was acquired by Merck & Co. in January 2020. Before joining ArQule in 2008, Mr. Pucci worked at Bayer A.G., where he served in several leadership capacities including Senior Vice President of the Global Specialty Medicine Business Unit and was a member of the Bayer Pharmaceuticals Global Management Committee. Before Bayer, Mr. Pucci held positions of increasing responsibility with Eli Lilly and Company, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci serves on the Board of Directors for Replimune Group, Inc., and in January of 2025, was appointed to be an independent Non-Executive Director to the Board of Directors of the Chiesi Group, a private global research-oriented biopharmaceutical company, where he also serves as Chair of the Strategy/Sustainability/Innovation Committee. He previously served on the Board of Directors of Merus N.V. and Trillium Therapeutics Inc. in addition to several other companies.